42 studies found for:    Inclusion Body Myositis
Show Display Options
RSS Create an RSS feed from your search for:
Inclusion Body Myositis
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Arimoclomol in Sporadic Inclusion Body Myositis
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
2 Active, not recruiting Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Conditions: Becker Muscular Dystrophy;   Sporadic Inclusion Body Myositis
Intervention: Biological: rAAV1.CMV.huFollistatin344
3 Completed Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Biological: BYM338;   Biological: Placebo
4 Not yet recruiting Study of Arimoclomol in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
5 Active, not recruiting An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Condition: Sporadic Inclusion Body Myositis
Interventions: Drug: Bimagrumab;   Drug: Placebo
6 Completed Blood-flow Restricted Exercise in Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Other: Blood-flow restricted training;   Drug: Care as usual
7 Recruiting Natalizumab in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis (IBM)
Intervention: Drug: Natalizumab
8 Active, not recruiting Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis (sIBM)
Intervention: Drug: BYM338 (Bimagrumab)
9 Completed Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
Conditions: Dermatomyositis;   Inclusion Body Myositis;   Polymyositis
Intervention: Drug: Gamma Globulin
10 Completed Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention: Drug: Etanercept
11 Completed Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention:
12 Completed Immune Abnormalities in Sporadic Inclusion Body Myositis
Conditions: Sporadic;   Inclusion Body;   Myositis
Intervention:
13 Completed Alemtuzumab to Treat Sporadic Inclusion Body Myositis
Condition: Myositis, Inclusion Body
Intervention: Drug: Alemtuzumab (Campath)
14 Active, not recruiting Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Condition: Sporadic Inclusion Body Myositis
Interventions: Drug: BYM338/bimagrumab;   Drug: Placebo
15 Completed Lithium in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Intervention:
16 Recruiting Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Condition: Inclusion Body Myositis (IBM)
Interventions: Drug: Rapamycin;   Drug: Placebo
17 Completed Anakinra in Myositis
Conditions: Polymyositis;   Dermatomyositis;   Inclusion Body Myositis
Intervention: Drug: Anakinra
18 Recruiting Adult and Juvenile Myositis
Conditions: Dermatomyositis;   Polymyositis;   Inclusion Body Myositis
Intervention:
19 Not yet recruiting MYOPROSP - a Prospective Cohort Study in Myositis
Conditions: Myositis;   Idiopathic Inflammatory Myopathy
Intervention:
20 Unknown  A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Condition: Idiopathic Inflammatory Myopathy
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years